NASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis $7.08 -0.07 (-0.98%) (As of 02:43 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cytek Biosciences Stock (NASDAQ:CTKB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytek Biosciences alerts:Sign Up Key Stats Today's Range$7.00▼$7.2350-Day Range$4.69▼$7.4052-Week Range$4.66▼$9.87Volume440,905 shsAverage Volume695,079 shsMarket Capitalization$931.09 millionP/E RatioN/ADividend YieldN/APrice Target$9.17Consensus RatingBuy Company OverviewCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More… With the “Bitcoin Loophole” you can help supercharge the gains by 10x or more! (Ad)You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!>> Tap here to sign up and join them for the imminent workshop Cytek Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks70th Percentile Overall ScoreCTKB MarketRank™: Cytek Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 452nd out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCytek Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCytek Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Cytek Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.11) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -88.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -88.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cytek Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.59% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Cytek Biosciences has recently decreased by 6.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.59% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Cytek Biosciences has recently decreased by 6.04%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.78 News SentimentCytek Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.Search Interest2 people have searched for CTKB on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Cytek Biosciences is held by insiders.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cytek Biosciences' insider trading history. Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Stock News HeadlinesCytek Biosciences (NASDAQ:CTKB) Trading Up 26.7% After Earnings BeatNovember 8, 2024 | americanbankingnews.comCytek Biosciences introduces ESP Detection Option for Cytek AuroraNovember 7, 2024 | markets.businessinsider.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.November 12, 2024 | Weiss Ratings (Ad)Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterNovember 7, 2024 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock, Short Interest ReportNovember 7, 2024 | benzinga.comPositive Outlook and Buy Rating for Cytek Biosciences Amid Strong International Performance and Strategic ExpansionNovember 7, 2024 | markets.businessinsider.comCytek Biosciences Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | markets.businessinsider.comCytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...November 6, 2024 | finance.yahoo.comSee More Headlines CTKB Stock Analysis - Frequently Asked Questions How have CTKB shares performed this year? Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB shares have decreased by 22.0% and is now trading at $7.11. View the best growth stocks for 2024 here. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The business had revenue of $51.50 million for the quarter, compared to analyst estimates of $50.63 million. Cytek Biosciences had a negative net margin of 5.05% and a negative trailing twelve-month return on equity of 2.58%. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. Who are Cytek Biosciences' major shareholders? Cytek Biosciences' top institutional shareholders include Brown Capital Management LLC (7.22%), Charles Schwab Investment Management Inc. (0.78%), Connor Clark & Lunn Investment Management Ltd. (0.47%) and Principal Financial Group Inc. (0.38%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, Jack Ball and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cytek Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings11/05/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:CTKB CUSIPN/A CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$9.17 High Stock Price Target$10.00 Low Stock Price Target$8.50 Potential Upside/Downside+29.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,150,000.00 Net Margins-5.05% Pretax Margin-5.92% Return on Equity-2.58% Return on Assets-2.05% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.38 Sales & Book Value Annual Sales$193.01 million Price / Sales4.84 Cash Flow$0.03 per share Price / Cash Flow279.51 Book Value$2.93 per share Price / Book2.42Miscellaneous Outstanding Shares131,510,000Free Float118,881,000Market Cap$933.72 million OptionableOptionable Beta1.32 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:CTKB) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWhy Trump’s Win Can’t Stop the Coming Crisis - Protect Yourself NowNo matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBreaking News: Are Trump/Musk Planning an AI Takeover? (Shocking)Now that he is Donald Trump’s right-hand man… You owe it to yourself to see Elon Musk’s big AI prediction f...Traders Agency | SponsoredJ.D. Vance: Wall Street Will Tank Bonds to Sabotage TrumpJ.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a deat...Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.